These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 15447991)

  • 1. Enhancement of xenograft tumor radiosensitivity by the histone deacetylase inhibitor MS-275 and correlation with histone hyperacetylation.
    Camphausen K; Scott T; Sproull M; Tofilon PJ
    Clin Cancer Res; 2004 Sep; 10(18 Pt 1):6066-71. PubMed ID: 15447991
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Radiosensitization by SAHA in experimental colorectal carcinoma models-in vivo effects and relevance of histone acetylation status.
    Folkvord S; Ree AH; Furre T; Halvorsen T; Flatmark K
    Int J Radiat Oncol Biol Phys; 2009 Jun; 74(2):546-52. PubMed ID: 19427556
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antitumor activity of the histone deacetylase inhibitor MS-275 in prostate cancer models.
    Qian DZ; Wei YF; Wang X; Kato Y; Cheng L; Pili R
    Prostate; 2007 Aug; 67(11):1182-93. PubMed ID: 17520666
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Histone deacetylation as a target for radiosensitization.
    Cerna D; Camphausen K; Tofilon PJ
    Curr Top Dev Biol; 2006; 73():173-204. PubMed ID: 16782459
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vivo imaging of retinoic acid receptor beta2 transcriptional activation by the histone deacetylase inhibitor MS-275 in retinoid-resistant prostate cancer cells.
    Qian DZ; Ren M; Wei Y; Wang X; van de Geijn F; Rasmussen C; Nakanishi O; Sacchi N; Pili R
    Prostate; 2005 Jun; 64(1):20-8. PubMed ID: 15651062
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sulfonamide anilides, a novel class of histone deacetylase inhibitors, are antiproliferative against human tumors.
    Fournel M; Trachy-Bourget MC; Yan PT; Kalita A; Bonfils C; Beaulieu C; Frechette S; Leit S; Abou-Khalil E; Woo SH; Delorme D; MacLeod AR; Besterman JM; Li Z
    Cancer Res; 2002 Aug; 62(15):4325-30. PubMed ID: 12154036
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synergistic in vivo antitumor effect of the histone deacetylase inhibitor MS-275 in combination with interleukin 2 in a murine model of renal cell carcinoma.
    Kato Y; Yoshimura K; Shin T; Verheul H; Hammers H; Sanni TB; Salumbides BC; Van Erp K; Schulick R; Pili R
    Clin Cancer Res; 2007 Aug; 13(15 Pt 1):4538-46. PubMed ID: 17671140
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MS-27-275, an inhibitor of histone deacetylase, has marked in vitro and in vivo antitumor activity against pediatric solid tumors.
    Jaboin J; Wild J; Hamidi H; Khanna C; Kim CJ; Robey R; Bates SE; Thiele CJ
    Cancer Res; 2002 Nov; 62(21):6108-15. PubMed ID: 12414635
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Class I histone deacetylase-selective novel synthetic inhibitors potently inhibit human tumor proliferation.
    Park JH; Jung Y; Kim TY; Kim SG; Jong HS; Lee JW; Kim DK; Lee JS; Kim NK; Kim TY; Bang YJ
    Clin Cancer Res; 2004 Aug; 10(15):5271-81. PubMed ID: 15297431
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of the antitumor efficacy, pharmacokinetics, and pharmacodynamics of the histone deacetylase inhibitor depsipeptide in childhood cancer models in vivo.
    Graham C; Tucker C; Creech J; Favours E; Billups CA; Liu T; Fouladi M; Freeman BB; Stewart CF; Houghton PJ
    Clin Cancer Res; 2006 Jan; 12(1):223-34. PubMed ID: 16397046
    [TBL] [Abstract][Full Text] [Related]  

  • 11. YM753, a novel histone deacetylase inhibitor, exhibits antitumor activity with selective, sustained accumulation of acetylated histones in tumors in the WiDr xenograft model.
    Shindoh N; Mori M; Terada Y; Oda K; Amino N; Kita A; Taniguchi M; Sohda KY; Nagai K; Sowa Y; Masuoka Y; Orita M; Sasamata M; Matsushime H; Furuichi K; Sakai T
    Int J Oncol; 2008 Mar; 32(3):545-55. PubMed ID: 18292931
    [TBL] [Abstract][Full Text] [Related]  

  • 12. SULF1 inhibits tumor growth and potentiates the effects of histone deacetylase inhibitors in hepatocellular carcinoma.
    Lai JP; Yu C; Moser CD; Aderca I; Han T; Garvey TD; Murphy LM; Garrity-Park MM; Shridhar V; Adjei AA; Roberts LR
    Gastroenterology; 2006 Jun; 130(7):2130-44. PubMed ID: 16762634
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of the in vitro and in vivo antitumor activity of histone deacetylase inhibitors for the therapy of retinoblastoma.
    Dalgard CL; Van Quill KR; O'Brien JM
    Clin Cancer Res; 2008 May; 14(10):3113-23. PubMed ID: 18483379
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Substituted N-(2-aminophenyl)-benzamides, (E)-N-(2-aminophenyl)-acrylamides and their analogues: novel classes of histone deacetylase inhibitors.
    Moradei O; Leit S; Zhou N; Fréchette S; Paquin I; Raeppel S; Gaudette F; Bouchain G; Woo SH; Vaisburg A; Fournel M; Kalita A; Lu A; Trachy-Bourget MC; Yan PT; Liu J; Li Z; Rahil J; MacLeod AR; Besterman JM; Delorme D
    Bioorg Med Chem Lett; 2006 Aug; 16(15):4048-52. PubMed ID: 16713259
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antiproliferative and proapoptotic effects of histone deacetylase inhibitors on gastrointestinal neuroendocrine tumor cells.
    Baradari V; Huether A; Höpfner M; Schuppan D; Scherübl H
    Endocr Relat Cancer; 2006 Dec; 13(4):1237-50. PubMed ID: 17158768
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Relationship between embryonic histonic hyperacetylation and axial skeletal defects in mouse exposed to the three HDAC inhibitors apicidin, MS-275, and sodium butyrate.
    Di Renzo F; Broccia ML; Giavini E; Menegola E
    Toxicol Sci; 2007 Aug; 98(2):582-8. PubMed ID: 17517827
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro and in vivo radiosensitization induced by the ribonucleotide reductase inhibitor Triapine (3-aminopyridine-2-carboxaldehyde-thiosemicarbazone).
    Barker CA; Burgan WE; Carter DJ; Cerna D; Gius D; Hollingshead MG; Camphausen K; Tofilon PJ
    Clin Cancer Res; 2006 May; 12(9):2912-8. PubMed ID: 16675588
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enhanced radiation-induced cell killing and prolongation of gammaH2AX foci expression by the histone deacetylase inhibitor MS-275.
    Camphausen K; Burgan W; Cerra M; Oswald KA; Trepel JB; Lee MJ; Tofilon PJ
    Cancer Res; 2004 Jan; 64(1):316-21. PubMed ID: 14729640
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New method to detect histone acetylation levels by flow cytometry.
    Ronzoni S; Faretta M; Ballarini M; Pelicci P; Minucci S
    Cytometry A; 2005 Jul; 66(1):52-61. PubMed ID: 15915507
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A systematic assessment of radiation dose enhancement by 5-Aza-2'-deoxycytidine and histone deacetylase inhibitors in head-and-neck squamous cell carcinoma.
    De Schutter H; Kimpe M; Isebaert S; Nuyts S
    Int J Radiat Oncol Biol Phys; 2009 Mar; 73(3):904-12. PubMed ID: 19215824
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.